Methods of treating inflammation

Abstract

The present application is related to methods of treating ARDS in a subject in need thereof, by administering (a) pioglitazone, or a pharmaceutically acceptable salt thereof, and (b) mesenchymal stromal cells to the subject. Also disclosed herein are methods of treating one or more symptoms of ARDS in a subject in need thereof.

What is claimed is: 
     
         1 . A method of treating ARDS in a subject in need thereof, comprising administering (a) pioglitazone, or a pharmaceutically acceptable salt thereof, and (b) mesenchymal stromal cells. 
     
     
         2 . The method of  claim 1 , wherein the administration of (a) pioglitazone, or a pharmaceutically acceptable salt thereof, between about 3 to about 7 days prior to the administration of (b) mesenchymal stromal cells. 
     
     
         3 . The method of  claim 1 , wherein between about 1 mg and 10 mg of pioglitazone, or a pharmaceutically acceptable salt thereof, per kilogram body weight thereof is administered to the subject. 
     
     
         4 . The method of  claim 1 , wherein the mesenchymal stromal cells are administered intranasally. 
     
     
         5 . The method of  claim 1 , wherein the mesenchymal stromal cells are administered intravenously. 
     
     
         6 . The method of  claim 1 , wherein the mesenchymal stromal cells are administered intra-arterially or intra-cranially. 
     
     
         7 . The method of  claim 1 , wherein the pioglitazone, or a pharmaceutically acceptable salt thereof, is administered intranasally. 
     
     
         8 . The method of  claim 1 , further comprising administering (a) pioglitazone, or a pharmaceutically acceptable salt thereof, after the administration of (b) mesenchymal stromal cells. 
     
     
         9 . The method of  claim 8 , wherein the pioglitazone, or a pharmaceutically acceptable salt thereof, is administered for between about 1 day to about 7 days after the mesenchymal stromal cells. 
     
     
         10 . The method of  claim 1 , wherein about 0.5×10 6  to about 1×10 7  mesenchymal stromal cells per kilogram body weight are administered to the subject. 
     
     
         11 . A method of treating one or more symptoms of ARDS in a subject in need thereof, comprising administering (a) pioglitazone, or a pharmaceutically acceptable salt thereof, and (b) mesenchymal stromal cells. 
     
     
         12 . The method of  claim 11 , wherein the one or more symptoms are selected from: cough, shortness of breath, fast breathing, and low blood oxygen levels. 
     
     
         13 . The method of  claim 11 , wherein the administration of (a) pioglitazone, or a pharmaceutically acceptable salt thereof, is between about 3 days to 7 days prior to the administration of (b) mesenchymal stromal cells. 
     
     
         14 . The method of  claim 11 , wherein between about 1 mg and 10 mg of pioglitazone, or a pharmaceutically acceptable salt thereof, per kilogram body weight thereof is administered to the subject. 
     
     
         15 . The method of  claim 11 , wherein the mesenchymal stromal cells are administered intranasally or intravenously. 
     
     
         16 . The method of  claim 11 , wherein the mesenchymal stromal cells are administered intra-arterially or intra-cranially. 
     
     
         17 . The method of  claim 11 , wherein the pioglitazone, or a pharmaceutically acceptable salt thereof, is administered intranasally. 
     
     
         18 . The method of  claim 11 , further comprising administering (a) pioglitazone, or a pharmaceutically acceptable salt thereof, after the administration of (b) mesenchymal stromal cells. 
     
     
         19 . The method of  claim 18 , wherein the pioglitazone, or a pharmaceutically acceptable salt thereof, is administered for between about 1 day to about 7 days after the mesenchymal stromal cells. 
     
     
         20 . The method of  claim 11 , wherein about 0.5×10 6  to about 1×10 7  mesenchymal stromal cells per kilogram body weight are administered to the subject.